¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Áß¾Ó´ëÇб³±¤¸íº´¿ø Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸ P-TRG(Platelet-Thrombosis Research Group) 2022 : 2022-10-15

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Áß¾Ó´ëÇб³±¤¸íº´¿ø Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸ P-TRG(Platelet-Thrombosis Research Group) 2022 : 2022-10-15
±³À°ÀÏÀÚ : 2022-10-15
±³À°Àå¼Ò : Áß¾Ó´ëÇб³±¤¸íº´¿ø, ±èºÎ¼·È¦(5F)  
±³À°ÁÖÁ¦ : P-TRG(Platelet-Thrombosis Research Group) 2022
ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸  
´ã´çÀÚ : Á¶¿¹¸®
¿¬¶ôó : 02-582-8222  
À̸ÞÀÏ : yehc@kscvi.org      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 120¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °æ±âµµ
±³À°½Ã°£ : 7 ½Ã°£ 15ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í -Á¤È¸¿ø ¹«·á µî·Ï -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù.      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 09:00~09:10 Genotype-Guided Oral P2Y12 Inhibitor Therapy Reduces Cumulative Ischemic Events Following Percutaneous Coronary Intervention - A Prespecified Secondary Analysis of the TAILOR-PCI(Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention) Randomised Trial  Â÷Á¤ÁØ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 09:10~09:20 INVICTUS(Investigation of Rheumatic AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies) - Rivaroxaban versus VKA(Vitamin K antagonists) for Rheumatic Atrial Fibrillation  Çã¾Ö¿µ(°­¿øÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 09:20~09:30 PACIFIC-AMI(Acute Myocardial Infarction) - Efficacy and Safety of Factor XIa Inhibitor Asundexian on Top of Dual Antiplatelet Therapy after Acute Myocardial Infarction  ¿øÈ£¿¬(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 09:30~09:40 Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR(Transcatheter Aortic Valve Replacement) - ADAPT-TAVR(Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement)  °­µµÀ±(¿ï»êÀÇ´ë) 
Åä·Ð 10-15 ±èºÎ¼·È¦(5F) 09:40~10:00 Discussion  () 
È޽Ġ10-15  10:00~10:10 Coffee Break  () 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 10:10~10:25 Atherothrombotic Events after COVD-19 Vaccination in Korea  ³ª»óÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 10:25~10:40 Medical Management of COVID-19 Coagulopathy  Á¶Á¤·¡(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 10:40~10:55 Laboratory Approach for the Platelet Function Disorders  ¹Ú»óÇõ(¿ï»êÀÇ´ë) 
Åä·Ð 10-15 ±èºÎ¼·È¦(5F) 10:55~11:10 Discussion  () 
È޽Ġ10-15  11:10~11:20 Coffee Break  () 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 11:20~11:35 Treatment of AF(Atrial Fibrillation) in Korean Patients: Perspectives from the Big Data  ¾çÇʼº(Â÷ÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 11:35~11:50 Anti-thrombotic Therapy in AF(Atrial Fibrillation) PCI(Percutaneous Coronary Intervention) Patients: Interventionist  ÀÌÁ¾¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 11:50~12:05 Updates of Korean AF(Atrial Fibrillation) Guideline: What Is New?  ÀÌÁ¤¸í(°æÈñÀÇ´ë) 
Åä·Ð 10-15 ±èºÎ¼·È¦(5F) 12:05~12:20 Discussion  () 
±âŸ 10-15 ±èºÎ¼·È¦(5F) 12:20~12:30 P-TRG ÃÑȸ  () 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 12:30~12:45 Cutting-Edge Care of Pitavastatin+Ezetimibe Combination Therapy  ¹Ú¿ëÈÖ(°æ»óÀÇ´ë) 
½Ä»ç 10-15  12:45~13:30 Lunch Break  () 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 13:30~13:40 Aspirin Monotherapy Is Enough after 1-year post-PCI(Percutaneous Coronary Intervention)  ±Ç¿À¼º(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 13:40~13:50 DAPT(Dual Antiplatelet Therapy) Continuation Is Better in High-risk Patients after 1-year post-PCI(Percutaneous Coronary Intervention)  ÀüÈ£¼º(¿¬¼¼¿øÁÖÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 13:50~14:00 Clopidogrel Monotherapy Is Better in High-risk Patients after 1-year post-PCI(Percutaneous Coronary Intervention)  À̽ÂÁØ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 10-15 ±èºÎ¼·È¦(5F) 14:00~14:15 Discussion  () 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 14:15~14:25 Recent Data Review: Antithrombotic Therapy 1-year after PCI(Percutaneous Coronary Intervention) in AF(Atrial Fibrillation) Patient  À̽ÂÇå(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 14:25~14:35 NOAC(New Oral Anticoagulant) Alone Is Enough  ÁøÇÑ¿µ(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 14:35~14:45 NOAC(New Oral Anticoagulant) Alone Is Not Enough, Antiplatelet Agent with NOAC(New Oral Anticoagulant) Should Be Continued  ÃÖ±âÈ«(¼º±Õ°üÀÇ´ë) 
Åä·Ð 10-15 ±èºÎ¼·È¦(5F) 14:45~15:00 Discussion  () 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 15:00~15:15 Anticoagulant Strategy in Korean Patients  À̱âÈ«(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 15:15~15:30 Prognostic Implication of Polygenic Risk Score in Korean Population  À̽ÂÇ¥(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 15:30~15:45 Charateristics of Dyslipidemia and Treatment Issues in Korean Population  Á¤Ã¢Èñ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 15:45~16:00 Treatment Guide according to Thrombogenicity in Korean Patients  Á¤¿µÈÆ(Áß¾ÓÀÇ´ë) 
Åä·Ð 10-15 ±èºÎ¼·È¦(5F) 16:00~16:20 Discussion  () 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 16:20~16:30 Relapsed NSTEMI(Non-ST Segment Elevation Myocardial Infarction) due to Acute Gastrointestinal Bleeding after NSTEMI(Non-ST Segment Elevation Myocardial Infarction)  ±èµµ¿ø(Á¤ÇÑ»ù³»°úÀÇ¿ø) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 16:30~16:40 Acute Myocardial Infarction Patient with Severe Thrombocytopenia  ±èÇü¿À(»ïÀ°¼­¿ïº´¿ø) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 16:40~16:50 Successful PCI(Percutaneous Coronary Intervention) in Hemophilia A Patient with Acute Myocardial Infarction Occurring at a Prior Documented Minimal Coronary Artery Lesion  ¹Ú»ó¹Î(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 16:50~17:00 Triple Antithrombotic Treatment and Staged Elective PCI(Percutaneous Coronary Intervention) for Q-wave Myocardial Infarction with Suspected of Multiple Thrombus Occlusion  ¼­¿µÈÆ(°Ç¾çÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 17:00~17:10 MI(Myocardial Infarction) ȯÀÚ¿¡¼­ Staged Noninfarct-related Artery ½Ã¼ú Á÷ÈÄ ¹ß»ýÇÑ Infarct-related ArteryÀÇ Stent Thrombosis, ±×¸®°í ÀÌÀÇ Ä¡·á ÈÄ ¹ß»ýÇÑ Retroperitoneal Hemorrhage Áõ·Ê  ÀÌÀ籤(â¿øÆÄƼ¸¶º´¿ø) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 17:10~17:20 Thrombosis, Thrombosis, and Thrombosis in a Patient with STEMI(ST-elevation Myocardial Infarction) undergoing Primary PCI(Percutaneous Coronary Intervention)  ÀüÈ£¼º(¿¬¼¼¿øÁÖÀÇ´ë) 
±³À°½Ã°£ 10-15 ±èºÎ¼·È¦(5F) 17:20~17:30 Hemorrhoids Bleeding, Is That a Simple Matter?  Ãµ´ë¿µ(ÇѸ²ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Áß¾Ó´ëÇб³±¤¸íº´¿ø Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸ P-TRG(Platelet-Thrombosis Research Group) 2022 : 2022-10-15""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ÀÌ´ë¸ñµ¿º´¿ø ºñ´¢ÀÇÇаú ½ÉÆ÷Áö¾ö : 2022-10-15
´ÙÀ½±Û ´ëÇÑ»óºÎÀ§Àå°ü Ç︮ÄÚ¹ÚÅÍÇÐȸ È£³²Áöȸ Ãß°è½ÉÆ÷Áö¿ò : 2022-10-15
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20775 ¼­¿ï 2024³â °áÇÙ°ü¸®±³À° 1±â(1ÀÏÂ÷) : 2024-06-13 0 0 2024-05-27
20774 ºÎ»ê (¿Â¶óÀÎ) ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ ºÎ»ê¡¤¿ï»ê¡¤°æ³² ÁöºÎȸ 2024³â 06¿ù Çмú´ëȸ : 2024-06-13 0 0 2024-05-27
20773 ´ëÀü 2024 Á¦40ȸ ´ëÇѼҾƿܰúÇÐȸ Ãá°èÇмú´ëȸ ¹× 40Áֳ⠱â³äÇà»ç(1ÀÏÂ÷) : 2024-06-13 0 1 2024-05-27
20772 ´ë±¸ 2024 Á¦2Â÷ ´ëÇѺñ´¢ÀÇÇÐȸ ´ë±¸°æºÏÁöºÎÇÐȸ : 2024-06-13 0 3 2024-05-27
20771 ¼­¿ï ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2024³â Á¦19Â÷ Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-13 0 4 2024-05-27
20770 ¼­¿ï 2024 ´ëÇÑÈ­»óÇÐȸ Çмú´ëȸ(1ÀÏÂ÷) : 2024-06-13 0 2 2024-05-27
20769 ¼­¿ï 2024³â ±Ýõ±¸ÀÇ»çȸ 1Â÷ ¿¬¼ö±³À°(¿ì¿ïÁõ ¾àÁ¦, ÇǺÎÁúȯ, CBC¿Í LFT, À§¿°) : 2024-06-12 0 0 2024-05-27
20768 ¼­¿ï 2024 Á¦3ȸ ÀÌ°ÇÈñ ¼Ò¾Æ¾Ï¡¤Èñ±ÍÁúȯ ±Øº¹»ç¾÷ ¿¬±¸ÀÚ SKILL-UP Workshop : 2024-06-12 0 0 2024-05-27
20767 °æ±â ´ëÇÑÇǺΰúÇÐȸ Á¦78Â÷ °æ±âÁöºÎȸ ÇмúÁý´ãȸ : 2024-06-11 0 0 2024-05-27
20766 ±¤ÁÖ Á¦180Â÷ ´ëÇѼҾÆû¼Ò³â°úÇÐȸ ±¤ÁÖ¡¤Àü³²Áöȸ ÇмúÁý´ãȸ : 2024-06-11 0 2 2024-05-27
20765 ºÎ»ê ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ºÎ»ê,¿ï»ê,°æ³²Áöȸ - Á¦362Â÷ ¿ù·ÊÇмúȸ : 2024-06-11 0 10 2024-05-27
20764 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-06-11 0 5 2024-05-27
20763 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ(ÀÇ»ç) ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À° : 2024-06-11 0 5 2024-05-27
20762 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾÆÀÀ±ÞÀÇÇÐȸ Á¦ 32ȸ Á¤±â Áý´ãȸ : 2024-06-10 0 5 2024-05-27
20761 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø Á¦16ȸ KOALA Symposium 2024 : 2024-06-09 0 1 2024-05-27
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷